Drug intelligence / Profile preview

LP-128

Development stage: Phase 1
Lead developer: Lupeng Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

LP-128 is an investigational small molecule drug developed by Guangzhou Lupeng Pharmaceutical for the treatment of chronic hepatitis B. Its mechanism of action is as an inhibitor of hepatitis B surface antigen (HBsAg), aiming to reduce or eliminate HBsAg in patients with chronic hepatitis B infection. The drug is currently being evaluated in phase 1 clinical trials, primarily focused on assessing its safety, tolerability, and pharmacokinetics in healthy subjects. The route of administration under investigation is oral (capsule formulation)[1][2][6].

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on LP-128.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LP-128.

Explore the full profile